Top Patient Support Programs Differentiate Through Access and Affordability
Event summary
- Spherix Global Insights' 2026 Patient Services Dynamix™ research evaluated 51 branded patient support programs across 66 indications.
- Dupixent, Skyrizi, Tremfya, Keytruda, Darzalex, and Hemlibra emerged as leaders in patient support satisfaction.
- The study surveyed over 500 healthcare providers and 600 patients/caregivers, highlighting the importance of reducing access friction and supporting affordability.
- Key drivers of satisfaction vary by therapeutic area and stakeholder, with bridge and starter kits important for immunology, and nursing support critical for oncology.
The big picture
The research underscores that effective patient support programs are not about offering the most services but about addressing specific access and affordability challenges unique to each therapeutic area. This trend reflects a broader industry shift towards personalized patient engagement strategies, driven by the need to improve therapy adherence and reduce treatment delays. The findings suggest that companies investing in targeted, stakeholder-specific support programs are likely to see higher satisfaction and better market positioning.
What we're watching
- Program Customization
- Whether pharmaceutical companies can tailor patient support programs to specific therapeutic areas and stakeholder needs to maintain competitive advantage.
- Access Friction Reduction
- The pace at which leading programs integrate services that reduce administrative and access barriers, particularly in complex therapeutic areas like oncology and rare diseases.
- Stakeholder Alignment
- How well manufacturers balance the differing priorities of providers, practice staff, and patients in designing patient support programs.